Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 21;24(20):15422. doi: 10.3390/ijms242015422

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Changes in tube formation properties in control and patient EC. (A) Reduction in tubular structures in the EC of P1 and P2 compared to the healthy control independent of treatment with agalsidase-α. (B) Timepoint analysis showed reduction in total tube length in P2 and branch count in P1 compared to the control EC (n = 3 per clone, 2 clones per cell line, conducted with and without treatment). Abbreviations: rhAGAL: recombinant human agalsidase-α, P1,2: Fabry patients. Scale bar: 1 mm. Statistics: Friedman test. * = p < 0.05, ** = p < 0.01.